← Deal Flow

Syneron Bio

DeepSeries B

Advancing precision medicine through innovative cell and gene therapies

🌐 www.syneronbio.comLinkedInX / Twitter📍 CAEst. 2014👥 51-200 employees
1Rounds
0Articles
General InformationSyneron Bio is a California-based clinical-stage biopharmaceutical company focused on cell and gene therapies, founded in 2014, with approximately 51-200 employees.
Funding & FinancialsThe company has raised multiple rounds of institutional funding with Series B as the most recent disclosed stage, backed by biotech-focused venture investors.
Leadership & TeamSyneron Bio is led by experienced biotech executives with backgrounds in cell therapy and oncology, though specific current leadership details require verification from recent company announcements.
Recent ActivityThe company continues advancing its pipeline of cell and gene therapy candidates through clinical development, with ongoing focus on expanding its therapeutic platform capabilities.

Highlights

Total Raised
1 rounds
Latest Round
$150
Apr 19, 2026
Stage
Series B
deep-tech
Employees
51-200
Founded 2014
Headquarters
CA
News Coverage
Talent Signals
SEC Filings

Backers

Abu Dhabi Investment Authority
AstraZeneca
BioTrack
CDH VGC
Decheng Capital
Qiming Venture Partners
True Light Capital

Funding History

$150
2026
Series B
SEC Form D   Editorial
Apr 19, 2026
$150 millionSeries B · Editorial

Investors: Decheng Capital, CDH VGC, True Light Capital, Qiming Venture Partners, BioTrack, AstraZeneca, Abu Dhabi Investment Authority

Macrocyclic peptide biotech company using AI platform Synova for drug development raised $150M Series B on April 3, 2026.

Similar Companies 6